Skip to Content
  • 3.1
    Impact Factor
  • 6.0
    CiteScore
  • 26 days
    Submission to First Decision
  • 4 days
    Acceptance to Publication

Tropical Medicine and Infectious Disease

Tropical Medicine and Infectious Disease (TropicalMed) is an international, peer-reviewed, open access journal of tropical medicine and infectious disease, and is published monthly online. The Australasian College of Tropical Medicine (ACTM) and its joint Faculties of Travel Medicine and Expedition and Wilderness Medicine are affiliated with the journal, serving as their official journal. College members receive discounts on the article processing charges.
  • Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
  • High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Informit, and other databases.
  • Journal Rank: JCR - Q2 (Tropical Medicine) / CiteScore - Q1 (Public Health, Environmental and Occupational Health)
  • Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 25.9 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the first half of 2026).
  • Recognition of Reviewers: Reviewers whose reports are timely and of high quality receive an APC discount voucher for a future publication in an MDPI journal. Become a reviewer.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (2,675)

  • Article
  • Open Access

Human parvovirus B19 (B19V) usually causes self-limiting infection but can cause severe complications in pregnancy, chronic hemolytic disease, and immunocompromise. Contemporary data on B19V immunity in Southeast Asia remain limited. We conducted an age-stratified, cross-sectional serosurvey of 430 residual specimens from four Thai provinces (April to August 2024) and compared findings against published age-specific data from 13 countries. Anti-B19V IgG was measured by quantitative ELISA, with seropositivity defined as 5.5 IU/mL or higher. Overall, 87 of 430 participants (20.2%; 95% CI, 16.5 to 24.3%) were seropositive, with a non-monotonic age pattern: 31.7% among children aged 0 to 5, falling to 4.7% at 6 to 12 years, then rising to 51.2% among those 60 and older. A serocatalytic model estimated an average constant force of infection of 8.5 per 1000 person-years beyond age 6; the present data did not provide evidence for the concentrated school-age transmission peak reported in Japan and Europe. From school age onward, Thai seroprevalence was toward the lower end of published estimates, a pattern shared with other Southeast and East Asian settings, although differences in assays, sampling frames, and study periods limit direct comparison. Seroprevalence was similarly elevated among children aged 1 to 2 and 3 to 5 years, and was therefore not concentrated in infancy; most seropositive young children had IgG concentrations close to the assay cut-off, and the explanation for this pattern remains uncertain. No significant differences by sex or province were observed. These findings suggest that a substantial proportion of adolescents and adults in the populations sampled lack detectable anti-B19V IgG and may remain susceptible to infection.

Study design, sampling framework, and demographic distribution of study participants. (a) Overview of specimen collection and testing workflow. (b) Geographic distribution of study participants across four provinces, one from each of the four regions of Thailand: Uttaradit (North, n = 106), Phra Nakhon Si Ayutthaya (Central, n = 108), Buri Ram (Northeast, n = 108), and Trang (South, n = 108). Donut charts show the proportion of participants contributed by each district within each province. (c) Age- and sex-specific distribution of study participants (n = 430), presented as a population pyramid showing the number and percentage of male and female participants in each age group.
  • Correction
  • Open Access

In the original publication [...]

  • Article
  • Open Access

Hepatitis E virus genotype 3 (HEV-3) is a zoonotic pathogen whose burden in Latin America remains underestimated. We conducted a cross-sectional One Health surveillance study (2019–2024) in Quindío, Colombia, testing 42 pig fecal, 8 farm runoff, 4 tributary water samples, and 5 clinical serum samples from patients with hepatitis of undetermined etiology by reverse transcription quantitative PCR (RT-qPCR). Positive and selected clinical/environmental samples underwent Oxford Nanopore MinION sequencing targeting the open reading frame 2 and 3 (ORF2/ORF3) junction, k-mer fingerprinting (k = 25), consensus generation, phylogenetic analysis, and Sanger confirmation. HEV RNA was detected in 8/42 pig fecal samples (19.0%), 4/8 runoff samples (50.0%), 1/4 tributary samples (25.0%), and 4/5 serum samples (80.0%). K-mer analysis identified strong HEV signals in two clinical samples (44.5% and 39.5% of reads) and wastewater (97.2%). Phylogenetic analysis classified Colombian isolates within HEV-3 (bootstrap 83%), while Sanger sequencing confirmed HEV-specific motifs. Two sequences were deposited in GenBank (PZ262436, PZ262437), representing the first Colombian HEV-3 genomic records. These findings demonstrate HEV-3 circulation across porcine, environmental, and human compartments and highlight substantial genomic divergence, supporting locally calibrated molecular approaches and strengthened One Health genomic surveillance in Colombia and Latin America.

  • Article
  • Open Access

Objective: The serum levels of high mobility group box 1 (HMGB1), the receptor for advanced glycation end products (RAGE), endogenous secretory RAGE (esRAGE), S100 calcium-binding protein A12 (S100A12), and advanced glycation end products (AGEs) were measured in patients with acute brucellosis and control subjects to elucidate the association between brucellosis and the HMGB1/RAGE pro-inflammatory axis, ultimately providing more scientific evidence for the prevention and control of the disease. Methods: A total of 112 patients with acute brucellosis were enrolled as the case group, and 119 healthy individuals were enrolled as the control group. Serum levels of HMGB1, RAGE, esRAGE, S100A12, and AGEs were determined by enzyme-linked immunosorbent assay (ELISA). The differences in serum levels of each indicator between groups were compared, and Pearson correlation analysis was employed to explore the correlations among HMGB1, RAGE, esRAGE, S100A12, and AGEs in the serum of brucellosis patients. Results: The serum level of HMGB1 in the case group was (9.188 ± 3.249) ng/mL, and that in the control group was (7.687 ± 2.385) ng/mL. A statistically significant difference in serum HMGB1 level was observed between the two groups (t = 4.019, p < 0.05). The serum level of RAGE in the case group was (3.847 ± 0.940) ng/mL, and those in the control group were (3.480 ± 0.930) ng/mL. A statistically significant difference in serum RAGE level was found between the two groups (t = 2.986, p < 0.05). The serum level of AGEs in the case group was (325.5 ± 144.2) μg/mL, and those in the control group were (356.6 ± 84.5) μg/mL. A statistically significant difference in serum AGE level was detected between the two groups (t = −2.009, p < 0.05). No statistically significant differences in serum levels of esRAGE and S100A12 were identified between the two groups. Conclusions: Serum levels of HMGB1, RAGE, and AGEs were found to be abnormally altered in patients with acute brucellosis. These changes suggest that HMGB1, RAGE, and AGEs may play a role in the host’s early immune response to Brucella. However, as this study only measured the circulating concentrations of these cytokines, further mechanistic studies are required to verify whether the observed alterations are involved in the signal transduction pathways of the Brucella-induced inflammatory response in the host.

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

Emerging Trends of Infectious Diseases in Canada
Reprint

Emerging Trends of Infectious Diseases in Canada

Editors: Yazdan Mirzanejad
Beyond Borders
Reprint

Beyond Borders

Tackling Neglected Tropical Viral Diseases
Editors: Jelena Prpić
XFacebookLinkedIn
Trop. Med. Infect. Dis. - ISSN 2414-6366